Bioage Labs
BioAge Labs Inc is an American clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of human aging. The company utilizes a data-driven biology platform to discover drug targets, advancing lead candidate azelaprag, an oral apelin receptor agonist for obesity in combination with incretin therapies. Main revenue drivers currently comprise investment capital financing, strategic pharmaceutical partnerships, and development milestone payments as clinical trials progress. BioAge Labs targets endocrinologists, obesity clinical networks, biopharmaceutical collaborators, and metabolic disease patients in North America. The company holds an innovative position in longevity-driven metabolic drug discovery and combination obesity therapeutics. Headquartered in Richmond, California, BioAge Labs Inc is listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Bioage Labs.
- Legal name
- Bioage Labs Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Obesity, Obesity & Metabolic Health, Ageing Biology, Ageing & Longevity, Geroscience
Funds holding Bioage Labs
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.08 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)